Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,216 across all filing types
Latest filing 2024-10-21 Board/Management Inform…
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events that shareholders should know about. The content specifically details the appointment of a new Chief Financial Officer, including biographical information, terms of employment, and compensation arrangements. This corresponds to announcements about changes in the company's board of directors or senior management. There is no financial data or report content such as earnings or annual report information. The document is not a report itself but a regulatory filing announcing management changes. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2024-10-21 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure of the Chief Financial Officer and the appointment of an interim CFO, including employment terms and compensation details. This fits the description of announcements related to changes in the company's board of directors or senior management. The document is not a full financial report, earnings release, or other types of filings. Therefore, it should be classified as Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2024-09-27 English
FORM 4
Director's Dealing
2024-09-14 English
Regulatory Filings 2024
Regulatory Filings
2024-09-13 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 3, 2024, reporting on an event related to the company's board of directors. Specifically, it details the outcome of a director's resignation tendered after receiving a majority of 'withhold' votes at the 2024 Annual Meeting of Stockholders. The document discusses the board's decision to reject the resignation and the director's continuation on the board. There are no financial statements or earnings data, nor is this a full annual or quarterly report. The content focuses on a change or potential change in the board of directors, which aligns with the category for Board/Management Information (MANG). The document length is about 4652 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the appropriate classification is MANG with high confidence.
2024-09-09 English
FORM 4
Director's Dealing
2024-08-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.